Latest updates for Hcvrx
Fresh curated links around HCVRX are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
- Hartford Conservative Allocation Fund Q2 2026 Commentary
- Prognosis? Improving
- INVIVYD
Post angles to try
Fresh articles and ideas
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
Prognosis? Improving
HCG has spent years expanding its cancer hospital network. Now utilisation, margins and returns may improve. Is the valuation discount an opportunity?
INVIVYD
INVIVYD Anonymous (not verified) Tue, 08/04/2026 - 21:28 field_thread_url https://cafepharma.com/boards/threads/invivyd.703943/ board na...
Heron (HRTX) Q2 2026 Earnings Call Transcript
Patent setback forces guidance withdrawal as acute care revenue surges 44% year over year.
Recursion (RXRX) Q2 2026 Earnings Call Transcript
AI-native drug discovery advances neuroscience target with Roche while cutting cash guidance.
CVS Health Corporation (CVS) Rose on Improving Execution and Payer Margin Outlook
CVS enhances supports for patients taking GLP-1s
CVS Health is raising its guidance for the year as it blew past Wall Street analysts' expectations in the second quarter.
XLV: Healthcare Sector On The Mend, But Probably Not For Long
Arcus: 'Buy' On Casdatifan Late-Stage CcRCC Advancement And 1st-Line Expansions
Atea outlines peak annual U.S. net revenue potential in excess of $700M with focus on mid-2028 HCV launch
HealthEquity’s (HQY) Health Savings Engine Hits A New Gear
CoreWeave: The Execution Story Is Flashing A Strong Signal (Rating Upgrade)
Hirogin Holdings, Inc. 2027 Q1 - Results - Earnings Call Presentation
Helus Pharma: APPROACHing Inflection: Pivotal Readout Sets Up Asymmetric Upside
2 Stocks That Could Capitalize on the GLP-1 Boom
They aren't the most prominent names in the GLP-1 space, but they are worth a second look.
Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment...
Revolution Medicines: Benefit Vs. Reality Compared To Peer Therapeutics
XOVR: The ETF That Lets Retail Investors Bet On Private Unicorns
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.